Home
About Us
AdAlta at a glance
Board
Management Team
Cancer Cell Therapies
“East to West” strategy
“East to West” product pipeline
I-Body Therapeutics
i-bodies
AD-214: A new approach to fibrotic disease
Fibrosis
Investors
Annual and Financial Reports
Presentations
Analyst Reports
ASX Announcements
News & Media
Corporate Governance
Contact Us
..Author:
IRM Support
Initial Director’s Interest Notice
August 24, 2016
Financial accounts to 29 February 2016
August 24, 2016
Financial accounts to 30 June 2015
August 24, 2016
Financial accounts to 30 June 2014
August 24, 2016
Financial accounts to 30 June 2013
August 24, 2016
Corporate Governance Policies and Committee Charters
August 24, 2016
Employee Share Option Plan
August 24, 2016
Constitution AdAlta
August 24, 2016
Distribution Schedule
August 24, 2016
Top Twenty
August 24, 2016
Posts navigation
Older posts
Newer posts
Archives
2016 News
Initial Director’s Interest Notice
AdAlta Extends Board with Appointment of US-Based Non Executive Director
Director Appointment
Results of AdAlta AGM 2016
AGM Presentation
2015 News
AdAlta and The University of Melbourne to develop i-bodies for the treatment of various eye diseases
Japanese patent granted for AdAlta i-body technology
AdAlta appoints Dr Paul MacLeman Chairman
AdAlta expands its scientific advisory team
2014 News
AdAlta expands its scientific advisory team
Lonza and AdAlta Announce a Strain Development Contract for Novel Biologic Therapeutics
2013 News
AdAlta collaborates with Crossbeta to find i-body for Alzheimer’s disease
AdAlta awarded voucher to explore benefits of technologies with Ferring Research Institute
2012 News
AdAlta and Baker IDI sign agreement to identify i-bodies to anti-thrombotic target
AdAlta and Roche sign agreement to evaluate shark antibody technology
2011 News
US patent granted for AdAlta i-body technology
AdAlta receives VC investment from Perth-based Yuuwa Capital